Clinical Trial Update: Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab with and without urelumab in cisplatin-ineligible or chemotherapy-refusing patients with muscle-invasive urothelial carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Urelumab (urelumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING